ChiCTR2600116790 版本V1.0 版本创建时间2026/01/15 08:50:58 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600116790 

最近更新日期:

Date of Last Refreshed on:

2026-01-15 08:50:51 

注册时间:

Date of Registration:

2026-01-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

牛乳中不同类型酪蛋白与肠道效应的关联研究

Public title:

A Study on the Association Between β-casomorphin Types in Cow's Milk and Intestinal Health

注册题目简写:

English Acronym:

研究课题的正式科学名称:

牛乳中不同类型酪蛋白与肠道效应的关联研究

Scientific title:

A Study on the Association Between β-casomorphin Types in Cow's Milk and Intestinal Health

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐玟 

研究负责人:

周明 

Applicant:

Xu Wen 

Study leader:

Zhou Ming 

申请注册联系人电话:

Applicant telephone:

+86 25 8686 8453

研究负责人电话:

Study leader's
telephone:

+86 25 8686 8453

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15158886369@163.com

研究负责人电子邮件:

Study leader's E-mail:

mzhou78@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市江宁区龙眠大道101号

研究负责人通讯地址:

江苏省南京市江宁区龙眠大道101号

Applicant address:

No. 101, Longmi Avenue, Jiangning District, Nanjing City, Jiangsu Province

Study leader's address:

No. 101, Longmi Avenue, Jiangning District, Nanjing City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学

Applicant's institution:

Nanjing Medical University

研究负责人所在单位:

南京医科大学

Affiliation of the Leader:

Nanjing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

南医大伦审〔2025〕152 号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京医科大学临床研究伦理审查委员会

Name of the ethic committee:

Ethics Committee of Nanjing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-05 00:00:00

伦理委员会联系人:

吴菲

Contact Name of the ethic committee:

Wu Fei

伦理委员会联系地址:

江苏省南京市江宁区龙眠大道101号

Contact Address of the ethic committee:

No. 101, Longmi Avenue, Jiangning District, Nanjing City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13851462776

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wufei@njmu.edu.cn

研究实施负责(组长)单位:

南京医科大学

Primary sponsor:

Nanjing Medical University

研究实施负责(组长)单位地址:

江苏省南京市江宁区龙眠大道101号

Primary sponsor's address:

No. 101, Longmi Avenue, Jiangning District, Nanjing City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学

具体地址:

江苏省南京市江宁区龙眠大道101号

Institution
hospital:

Nanjing Medical University

Address:

No. 101, Longmi Avenue, Jiangning District, Nanjing City, Jiangsu Province

经费或物资来源:

牛乳中不同类型酪蛋白与肠道效应的关联研究/至初牛奶(上海)有限公司

Source(s) of funding:

Corporate Grant from A2 Infant Nutrition (Shanghai) Co., Ltd.

研究疾病:

乳糖不耐症  

Target disease:

Lactose Intolerance

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.了解青年大学生乳糖不耐的患病情况; 2.探讨我国青年大学生饮奶后产生胃肠道症状与牛奶中含有的酪蛋白种类之间的关系;  

Objectives of Study:

1. Understand the prevalence of lactose intolerance among young college students; 2. Explore the relationship between gastrointestinal symptoms occurring after drinking milk by young college students in China and the types of casein contained in the milk.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经氢呼气试验后确定的乳糖耐受者; 2.18岁以上的在校大学生、研究生(包括硕士研究生、博士研究生); 3.同意在研究期间不服用任何药物、营养补充剂或其他乳制品; 4.愿意遵守所有要求和程序; 5.签署知情同意书; 6.同意在本研究期间不参与另一项介入性临床研究。

Inclusion criteria

1. Individuals with lactose tolerance identified through hydrogen breath test; 2. College students and graduate students (including master's and doctoral students) over 18 years old; 3. Agree not to take any medication, nutritional supplements or other dairy products during the study period; 4. Willing to comply with all requirements and procedures; 5. Sign the informed consent form; 6. Agree not to participate in another interventional clinical study during this research period.

排除标准:

1.乳糖不耐受者;
2.被认为可能干扰研究结果测量的任何进食障碍、代谢和/或慢性疾病;
3.入组时的急性感染或胃肠炎;
4.可能干扰研究结果测量的胃肠道疾病,如胃食管反流病、肠易激病或克罗恩病;
5.自我报告对牛奶产品过敏者;
6.医生诊断的免疫缺陷和任何严重疾病。

Exclusion criteria:

1. Lactose intolerants; 2. Any eating disorders, metabolic and/or chronic diseases that are considered potentially interfering with the measurement of research results; 3. Acute infections or gastroenteritis at the time of enrollment; 4. Gastrointestinal diseases that may interfere with the measurement of research results, such as gastroesophageal reflux disease, irritable bowel syndrome or Crohn's disease; 5. Individuals who self-report an allergy to milk products; 6. Individuals diagnosed with immunodeficiency and any serious diseases by doctors.

研究实施时间:

Study execute time:

From 2026-01-15 00:00:00 To 2026-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-15 00:00:00 To 2026-06-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

30

Group:

Experimental group

Sample size:

干预措施:

用仅含 A2 型酪蛋白的牛奶

干预措施代码:

Intervention:

Use milk that contains only A2 casein.

Intervention code:

组别:

对照组

样本量:

30

Group:

Control Group

Sample size:

干预措施:

普通商业牛奶

干预措施代码:

Intervention:

Regular commercial milk

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学 

单位级别:

 

Institution
hospital:

Nanjing Medical University

Level of the institution:

测量指标:

Outcomes:

指标中文名:

β-酪啡肽-7

指标类型:

主要指标

Outcome:

β-tyrosine peptide-7

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氢呼气值

指标类型:

主要指标

Outcome:

Hydrogen breath value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃肠道症状评分量表评分

指标类型:

主要指标

Outcome:

Gastrointestinal symptom score scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C-反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

唾液

组织:

Sample Name:

Saliva

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用分层随机化方法生成随机序列,由一名未参与后续研究的研究人员使用SAS 9.4软件生成随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization sequence was generated using a stratified randomization method by a researcher not involved in the subsequent trial procedures, with SAS 9.4 software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, with both the research participants and the researchers being blinded.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-01-15 08:50:51